Testing Potency and Efficacy of Inhibitors of P13K, SYK, BTK Activity

Inhibitors of PI3K, SYK and BTK pathways are a large focus for pharmaceutical companies with several small molecule inhibitors currently at different stages of development. Enzymatic assays measuring the direct activity of compounds are limited because they do not provide information about the entire pathway controlled by these kinases. If you are interested in learning more about how to overcome this limitation, you won’t want to miss this compelling webcast featuring Dr. Michele Romano from BÜHLMANN Laboratories AG.

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInEmail this to someone